Imatinib

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Aggressive Fibromatosis

Conditions

Aggressive Fibromatosis, Desmoid Tumor

Trial Timeline

Jun 1, 2010 → Dec 1, 2016

NCT ID

NCT01137916

About Imatinib

Imatinib is a phase 2 stage product being developed by Novartis for Aggressive Fibromatosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01137916. Target conditions include Aggressive Fibromatosis, Desmoid Tumor.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01392495	Phase 3	Terminated	Jun 1, 2011	Mar 1, 2014	Pulmonary Arterial Hypertension
NCT01137916	Phase 2	Completed	Jun 1, 2010	Dec 1, 2016	Aggressive Fibromatosis
NCT00760981	Phase 1	Completed	Sep 1, 2008	Apr 1, 2012	Graft vs Host Disease
NCT00632255	Pre-clinical	Completed	Jan 1, 2008	May 1, 2009	Chronic Myeloid Leukemia
NCT00426179	Phase 1/2	Completed	Dec 1, 2006	Aug 1, 2007	Seasonal Allergic Rhinitis
NCT00420043	Phase 1	Completed	Sep 1, 2006	Nov 1, 2006	Healthy
NCT00424515	Phase 2	Completed	Jul 1, 2006	Jul 1, 2011	Mucosal Melanoma
NCT00422825	Phase 1	Completed	Jun 1, 2006	Sep 1, 2006	Healthy
NCT00421317	Phase 2	Terminated	Dec 1, 2005	Nov 15, 2009	Melanoma
NCT00150072	Phase 2	Completed	Oct 1, 2004	Apr 1, 2008	Chordoma
NCT00237120	Phase 3	Completed	Nov 1, 2002	Jun 1, 2007	Chronic Myelogenous Leukemia in Chronic Phase
NCT00940563	Phase 2	Completed	Mar 1, 2002	—	Advanced Gastrointestinal Stromal Tumors

Competing Products

11 competing products in Aggressive Fibromatosis

See all competitors

Product	Company	Stage	Hype Score
ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy	Johnson & Johnson	Phase 2	52
Loncastuximab Tesirine and Epcoritamab	AbbVie	Phase 2	52
Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib	AstraZeneca	Phase 2	52
Midostaurin	Novartis	Phase 2	52
Bendamustine and subcutaneous rituximab	Roche	Phase 2	52
Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate	Bristol Myers Squibb	Phase 1/2	40
Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate	Bristol Myers Squibb	Phase 2	51
Vandetanib 300 mg	Sanofi	Pre-clinical	22
cemiplimab + odronextamab	Regeneron Pharmaceuticals	Phase 1	32
Zanzalintinib	Exelixis	Phase 2	49
PRT2527 + Zanubrutinib + Venetoclax	Prelude Therapeutics	Phase 1	25

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved